QVA149 administered once daily provides significant improvements in lung function over 1 year in patients with COPD: The ENLIGHTEN study
R. Dahl, K. Chapman, M. Rudolf, R. Mehta, P. Kho, V. Alagappan, I. Berhane, H. Chen, D. Banerji (Aarhus, Denmark; Toronto, Canada; London, Horsham, United Kingdom; Indore, India; East Hanover, United States Of America)
Source: Annual Congress 2012 - Pharmacological and non-pharmacological management of COPD
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
R. Dahl, K. Chapman, M. Rudolf, R. Mehta, P. Kho, V. Alagappan, I. Berhane, H. Chen, D. Banerji (Aarhus, Denmark; Toronto, Canada; London, Horsham, United Kingdom; Indore, India; East Hanover, United States Of America). QVA149 administered once daily provides significant improvements in lung function over 1 year in patients with COPD: The ENLIGHTEN study. Eur Respir J 2012; 40: Suppl. 56, 2896
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Once-daily QVA149 provides superior improvements in lung function compared with glycopyrronium and tiotropium in severe COPD patients: A 52 week pooled analysis Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013
NVA237 once daily provides rapid, clinically meaningful and sustained 24-h bronchodilation in patients with COPD: The GLOW1 trial Source: Annual Congress 2011 - Bronchodilators in asthma and COPD Year: 2011
Once-daily QVA149 demonstrates superior improvements in patient-reported dyspnea compared to tiotropium in patients with moderate-to-severe COPD: The BLAZE study Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013
QVA149 showed significant improvements in lung function and health status and was well tolerated versus glycopyrronium and tiotropium in patients with severe COPD: The SPARK study Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014
Indacaterol once-daily improves day and night-time symptom control in COPD patients: a 26-week study versus placebo and tiotropium Source: Annual Congress 2009 - New bronchodilators Year: 2009
QVA149 provides significant symptomatic benefit to COPD patients as measured by a new symptom e-diary: The SHINE study Source: International Congress 2015 – New data on established treatments for COPD Year: 2015
Patients with severe COPD show significant improvements in dyspnea and lung function with once-daily QVA149: The BLAZE study Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013
QVA149 is more efficacious than tiotropium and salmeterol/fluticasone combination (SFC) in improving patient-reported outcomes and lung function in COPD patients with moderate-to-severe baseline dyspnoea: The IGNITE trials Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015
Benefits of tiotropium/olodaterol compared with tiotropium in patients with COPD receiving only LAMA at baseline: pooled analysis of 4 clinical trials Source: International Congress 2019 – COPD clinical studies: bronchodilators, corticosteroids and more Year: 2019
Formoterol and tiotropium both improve lung function in stable COPD patients, with some additional benefit when given together Source: Eur Respir J 2006; 28: Suppl. 50, 429s Year: 2006
NVA237 once daily reduces the percentage of patients with exacerbations of COPD and associated hospitalizations: The GLOW1 trial Source: Annual Congress 2011 - New treatments for airway disease Year: 2011
Budesonide/formoterol in a single inhaler is well tolerated in patients with moderate to severe COPD: results of a 1-year study Source: Eur Respir J 2002; 20: Suppl. 38, 242s Year: 2002
Once-daily NVA237 improves lung function in COPD patients: Pooled results of the GLOW1 and GLOW2 studies Source: Annual Congress 2012 - COPD treatments: efficacy and safety Year: 2012
QVA149 once-daily is safe and well tolerated and improves lung function and health status in Japanese patients with COPD: The ARISE study Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013
Patient-reported outcomes (PROs) and reliever use in Japanese and European patients with chronic obstructive pulmonary disease receiving formoterol 4.5 and 9μg twice daily: Results of the OCEAN phase III study Source: Annual Congress 2010 - Pharmacological modulation of biomarkers and management Year: 2010
QVA149 improves dyspnoea and lung function versus tiotropium in symptomatic patients using LABA/ICS preceding study enrolment: The BLAZE study Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014
Once-daily QVA149 improves dyspnoea and health status compared with tiotropium plus formoterol in patients without ICS use: A post-hoc analysis of the QUANTIFY study Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015
Dual bronchodilation with once-daily QVA149 reduces exacerbations, improves lung function and health status versus glycopyrronium and tiotropium in severe-to-very severe COPD patients: The SPARK study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013
LATE-BREAKING ABSTRACT: Once-daily QVA149 significantly improves lung function and symptoms compared to twice-daily fluticasone/salmeterol in COPD patients: The ILLUMINATE study Source: Annual Congress 2012 - Exacerbations of asthma and COPD: assessment, impact and novel treatments Year: 2012
Indacaterol once-daily improves health-related quality of life in COPD patients: a 26-week comparison with placebo and tiotropium Source: Annual Congress 2009 - New bronchodilators Year: 2009